Literature DB >> 24501304

EMT twists the road to PI3K.

Matthew J Niederst1, Cyril H Benes.   

Abstract

Epithelial-to-mesenchymal transition (EMT) is important for many developmental events and has been linked to tumor dissemination and therapeutic resistance. Salt and colleagues identify how EMT affects how proliferation signals flow to phosphoinositide 3-kinase in non-small cell lung cancer. 2014 AACR

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24501304      PMCID： PMC3918580          DOI： 10.1158/2159-8290.CD-13-1030

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  12 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Authors:  Hiromichi Ebi; Ryan B Corcoran; Anurag Singh; Zhao Chen; Youngchul Song; Eugene Lifshits; David P Ryan; Jeffrey A Meyerhardt; Cyril Benes; Jeffrey Settleman; Kwok-Kin Wong; Lewis C Cantley; Jeffrey A Engelman
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

3.  Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.

Authors:  Shizhen Emily Wang; Bin Xiang; Marta Guix; Maria Graciela Olivares; Joel Parker; Christine H Chung; Atanasio Pandiella; Carlos L Arteaga
Journal:  Mol Cell Biol       Date:  2008-07-14       Impact factor: 4.272

4.  Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.

Authors:  Stéphane Ansieau; Jeremy Bastid; Agnès Doreau; Anne-Pierre Morel; Benjamin P Bouchet; Clémence Thomas; Frédérique Fauvet; Isabelle Puisieux; Claudio Doglioni; Sara Piccinin; Roberta Maestro; Thibault Voeltzel; Abdelkader Selmi; Sandrine Valsesia-Wittmann; Claude Caron de Fromentel; Alain Puisieux
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

Review 5.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

6.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

7.  Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.

Authors:  Megan B Salt; Sourav Bandyopadhyay; Frank McCormick
Journal:  Cancer Discov       Date:  2013-12-03       Impact factor: 39.397

8.  Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes.

Authors:  Gongda Xue; David F Restuccia; Qiang Lan; Debby Hynx; Stephan Dirnhofer; Daniel Hess; Curzio Rüegg; Brian A Hemmings
Journal:  Cancer Discov       Date:  2012-01-25       Impact factor: 39.397

9.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440
View more
  6 in total

1.  ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

Authors:  Niki Karachaliou; Ana Gimenez-Capitan; Ana Drozdowskyj; Santiago Viteri; Teresa Moran; Enric Carcereny; Bartomeu Massuti; Alain Vergnenegre; Filippo de Marinis; Miguel Angel Molina; Cristina Teixido; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2014-06

2.  TGFβ-induced epithelial-to-mesenchymal transition in prostate cancer cells is mediated via TRPM7 expression.

Authors:  Yuyang Sun; Anne Schaar; Pramod Sukumaran; Archana Dhasarathy; Brij B Singh
Journal:  Mol Carcinog       Date:  2018-03-15       Impact factor: 4.784

3.  FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC.

Authors:  Fengrui Zhou; Jianxiong Geng; Shanqi Xu; Qingwei Meng; Kexin Chen; Fang Liu; Fang Yang; Bo Pan; Yan Yu
Journal:  Aging (Albany NY)       Date:  2019-08-24       Impact factor: 5.682

4.  Combining radiation with PI3K isoform-selective inhibitor administration increases radiosensitivity and suppresses tumor growth in non-small cell lung cancer.

Authors:  Mi Youn Seol; Seo Hee Choi; Hong In Yoon
Journal:  J Radiat Res       Date:  2022-07-19       Impact factor: 2.438

5.  Super-enhancer-driven AJUBA is activated by TCF4 and involved in epithelial-mesenchymal transition in the progression of Hepatocellular Carcinoma.

Authors:  Chi Zhang; Shi Wei; Wei-Peng Sun; Kai Teng; Miao-Miao Dai; Feng-Wei Wang; Jie-Wei Chen; Han Ling; Xiao-Dan Ma; Zi-Hao Feng; Jin-Ling Duan; Mu-Yan Cai; Dan Xie
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

6.  PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition.

Authors:  Li-Ting Wang; Kwei-Yan Liu; Wen-Yih Jeng; Cheng-Ming Chiang; Chee-Yin Chai; Shyh-Shin Chiou; Ming-Shyang Huang; Kazunari K Yokoyama; Shen-Nien Wang; Shau-Ku Huang; Shih-Hsien Hsu
Journal:  EMBO Rep       Date:  2020-01-07       Impact factor: 8.807
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.